Chinese Journal of Integrative Medicine

, Volume 21, Issue 4, pp 312–320 | Cite as

Songling Xuemaikang Capsule (松龄血脉康胶囊) for primary hypertension: A systematic review of randomized controlled trials

  • Xiao-chen Yang (杨晓忱)
  • Xing-jiang Xiong (熊兴江)
  • Guo-yan Yang (杨国彦)
  • He-ran Wang (王贺冉)
  • Jie Wang (王 阶)Email author
Evidence-Based Integrative Medicine



To evaluate the effectiveness and safety of Songling Xuemaikang Capsule (松龄血脉康胶囊, SXC) for the treatment of primary hypertension.


An extensive search including Cochrane Library, PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), Chinese Biomedical Literature Database (CBM), Chinese National Knowledge Infrastructure (CNKI), Chinese Scientific Journal Database (VIP), KoreaMed, Japanese database, and online clinical trial registry websites was performed up to February 2013. Randomized controlled trials (RCTs) regarding SXC for the treatment of primary hypertension were searched without no language restrictions. The quality of each trial was assessed according to the Cochrane Reviewers’ Handbook 5.0, and RevMan 5.0 provided by the Cochrane Collaboration.


A total of 17 RCTs involving 1,778 patients were included. Meta-analysis showed that there was no significant difference between SXC and antihypertensive agents on systolic blood pressure [mean difference (MD): −0.10 [−4.83, 4.63]; P=0.97] and diastolic blood pressure (MD: 1.00 [−1.16, 3.16]; P=0.36), but SXC combined with antihypertensive drugs was more effective in lowering systolic blood pressure (MD: −6.17 [−7.86, −4.49]; P<0.00001) and diastolic blood pressure (MD: −7.24 [−8.62, −5.85]; P<0.00001) compared with the antihypertensive drugs alone.


SXC used alone or combined with antihypertensive drugs appear to be an effective treatment for lowering elevated blood pressure and improving symptoms in patients with primary hypertension. However, the conclusion cannot be drawn definitely due to the poor quality of the included studies. There is still an urgent need for well-designed, long-term studies to address the benefits of SXC for treating primary hypertension.


Songling Xuemaikang Capsule primary hypertension Chinese patent medicine systematic review randomized controlled trials 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a metaanalysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903–1913.CrossRefPubMedGoogle Scholar
  2. 2.
    Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA 2003;289:2560–2571.CrossRefPubMedGoogle Scholar
  3. 3.
    Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA 2005;294:466–72.CrossRefPubMedGoogle Scholar
  4. 4.
    Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004;43:10–17.CrossRefPubMedGoogle Scholar
  5. 5.
    Turner AJ, Hooper NM. The angiotensin-converting enzyme gene family: genomics and pharmacology. Trends Pharmacol Sci 2002;23:177–83.CrossRefPubMedGoogle Scholar
  6. 6.
    Wang Y, Wang QJ. The prevalence of prehypertension and hypertension among US adults according to the New Joint National Committee guidelines: new challenges of the old problem. Arch Intern Med 2004;164:2126–2134.CrossRefPubMedGoogle Scholar
  7. 7.
    Choi KM, Park HS, Han JH, Lee JS, Lee J, Ryu OH, et al. Prevalence of prehypertension and hypertension in a Korean population: Korean National Health and Nutrition Survey 2001. J Hypertens 2006;24:1515–1521.CrossRefPubMedGoogle Scholar
  8. 8.
    InterASIA Collaborative Group. Cardiovascular risk factor levels in urban and rural Thailand—The International Collaborative Study of Cardiovascular Disease in Asia (InterASIA). Eur J Cardiovasc Prev Rehabil 2003;10:249–257.CrossRefGoogle Scholar
  9. 9.
    Ramsay LE, Wallis EJ, Yeo WW, Jackson PR. Absolute and relative risk in hypertension. In: Bulpitt CJ, ed. Handbook of hypertension. Amsterdam: Elsevier Science BV; 2000:43–57.Google Scholar
  10. 10.
    Menotti A, Puddu PE, Lanti M. Comparison of the Framingham risk function-based coronary chart with risk function from and Italian population study. Eur Heart J 2000;21:365–370.CrossRefPubMedGoogle Scholar
  11. 11.
    Ernst E, Resch KL, Mills S, Hill R, Mitchell A, Willoughby M, et al. complementary medicine—a definition. Br J Gen Pract 1995;45:506–511.PubMedCentralGoogle Scholar
  12. 12.
    Ernst E. Complementary/alternative medicine for hypertension: mini-review. Wien Med Wochenschr 2005;155:386–391.CrossRefPubMedGoogle Scholar
  13. 13.
    Huang ZG, Zhang NB. Effect of puerarin on structure and function of thoracic aorta in spontaneously hypertensive rats. Chin J Pharmacol Toxic (Chin) 2012;26:595–601.Google Scholar
  14. 14.
    Park G, Paudyal DP, Hwang I. Production of fermented needle extracts from red pine and their functional characterization. Biotechnol Bioproc Eng 2008;13:256–261.CrossRefGoogle Scholar
  15. 15.
    Kwak CS, Moon SC, Lee MS. Antioxidant, antimutagenic, and antitumor effects of pine needles (Pinus densiflora) preview. Nutrit Cancer 2009;18:162–171.Google Scholar
  16. 16.
    Shono M, Shimizu I, Aoyagi E, Taniguchi T, Takenaka H, Ishikawa M, et al. Reducing effect of feeding powdered nacre of Pinctada maxima on the visceral fat of rats. Biosci Biotechnol Biochem 2008;72:2761–2763.CrossRefPubMedGoogle Scholar
  17. 17.
    Xiao MF, Zhou D. Effects of “Huoxue Qianyang Granule” on renin-angiotensin system in plasma of spontaneous hypertensive rats. Shanghai J Tradit Chin Med (Chin) 2007;41:59–61.Google Scholar
  18. 18.
    Wan WH, Xiong WB, Zhu L. The antihypertensive effect and mechanism of Songling Xuemaikang Capsule on spontaneously hypertensive rats. Sichuan J Physiol Sci (Chin) 2005;27:133–144.Google Scholar
  19. 19.
    Kjeldsen SE, Erdine S, Farsang C, Sleight P, Mancia G. 1999 WHO/ISH hypertension guidelines—highlights & ESH update. Blood Press 2003;12:181–182.PubMedGoogle Scholar
  20. 20.
    Higgins JPT, Green S. Corchrane reviewers’ handbook 5.1.0 [updated March 2011]. Review Manager (RevMan) [Computer program]. Version 5.1.0.Google Scholar
  21. 21.
    Shen M. Clinical observation of Songling Xuemaikang Capsule in combination with amlodipine on patients with senile hypertension. J Pract Med (Chin) 2012;28:1711–1712.Google Scholar
  22. 22.
    Ge CY. Clinical observation of Songling Xuemaikang Capsule in combination with amlodipine on patients with senile hypertension. Chin J Integr Med Cardio-/Cerebrovasc Dis (Chin) 2012;10:515–517.Google Scholar
  23. 23.
    Wang Q, Qiao K. The comparison of Songling Xuemaikang Capsule and nifedipine on treating primary hypertension. West China J Pharmac Sci 2006;1:107–108.Google Scholar
  24. 24.
    Li YD, Liu D, Dong CH. Effects of Songling Xuemaikang Capule on heart rate variability of patients with hypertension. J Clin Electrocardiol (Chin) 2011;5:354–356.Google Scholar
  25. 25.
    Li H. Clinical observation of Songling Xuemaikang Capsule combined with valsartan in patients with hypertension. Chin J Integr Med Cardio-/Cerebrovasc Dis (Chin) 2011;9:911–912.Google Scholar
  26. 26.
    Yin BD. Clinical observation of Songling Xuemaikang Capsule combined with losartan on 76 cases of primary hypertension. Med Inform (Chin) 2011;24:4926–4927.Google Scholar
  27. 27.
    Cui JJ, Wei L, Peng DL. Efficacy assessment of Songling Xuemaikang Capsule on the quality of life in patients with hypertension. Chin J Integr Med Cardio-/Cerebrovasc Dis (Chin) 2011;9:533–534.CrossRefGoogle Scholar
  28. 28.
    Wang FQ. The efficacy of Songling Xuemaikang Capsule combined with amlodipine on reduction of blood pressure variability on patients with primary hypertension. Jilin J Tradit Chin Med (Chin) 2011;31:149–150.Google Scholar
  29. 29.
    Xu LR, Gao XW, Chen JX. Clinical effect of Songling Xuemaikang Capsule on 180 patients in excess liver-yang with elderly hypertension. Fujian J Tradit Chin Med (Chin) 2010;41:45–46.Google Scholar
  30. 30.
    Li XY, Du YB, Chen WL. Effects of Songling Xuemaikang Capsule on blood pressure and left ventricular hypertrophy in patients with elderly hypertension. Yunnan J Tradit Chin Med Mater Med (Chin) 2009;30:10–12.Google Scholar
  31. 31.
    Liu J. Clinical observation of Songling Xuemaikang Capsule combined with benazepril in the treatment of non-dipper hypertension. Med J Commun (Chin) 2007;21:648–649.Google Scholar
  32. 32.
    He ZM, Liang YR. Discussion of valsartan combined with Songling Xuemaikang Capsule on treatment of primary hypertension. Pract J Cardiac Cerebral Pneumal Vasc Dis (Chin) 2006;14:968–969.Google Scholar
  33. 33.
    Wang Q, Qiao K. The comparison of Songling Xuemaikang Capsule with nifedipine GITS on treatment of primary hypertension. West China J Pharmac Sci (Chin) 2006;21:107–108.Google Scholar
  34. 34.
    Weng JL, Zhang FW. Clinical observation of Songling Xuemaikang Capsule combined with losartan potassium in patients with excess liver-yang and hypertension. Chin General Pract (Chin) 2005;8:933–935.Google Scholar
  35. 35.
    Wang F, Kang J. Clinicla observation of Songling Xuemaikang Capsule on primary hypertension. China Naturop (Chin) 2004;12:57–59.Google Scholar
  36. 36.
    Chen WQ, Chen FR. Effects of Songling Xuemaikang Capsule combined with captopril on the quality of life of patients with primary hypertension. Chin J Integr Tradit West Med (Chin) 2001;21:660–662.Google Scholar
  37. 37.
    Wang YT, Guo YG. Clinical observation of Songling Xuemaikang Capsule on treatment of hypertension. Strait Pharmac J (Chin) 1997;9:37–38.Google Scholar
  38. 38.
    Xiong XJ, Yang XC, Liu YM, Zhang Y, Wang PQ, Wang J. Chinese herbal formulas for treating hypertension in traditional Chinese medicine: perspective of modern science. Hypert Res 2013;36:570–579.CrossRefGoogle Scholar
  39. 39.
    Xiong XJ, Yang XC, Liu W, Chu FY, Wang PQ, Wang J. Trends in the treatment of hypertension from the perspective of traditional Chinese medicine. Evid Based Complem Altern Med 2013; 1–13, Article ID 275279.Google Scholar
  40. 40.
    Wang J, Xiong XJ, Zhang YQ, Liu YM, Zhang Y, Zhang ZP, et al. Chinese herbal medicine qi ju di huang wan for the treatment of essential hypertension: a systematic review of randomized controlled trials. Evid Based Complemt Alternat Med 2013;2013:262685.Google Scholar
  41. 41.
    Wang JS, Heijden RVD, Spruit S, Hankermeier T, Chan K, Greef JVD, et al. Quality and safety of Chinese herbal medicines guided by a systems biology perspective. J Ethnopharmacol 2009;126:31–41.CrossRefPubMedGoogle Scholar
  42. 42.
    Chan K. Some aspects of toxic contaminants in herbal medicines. Chemosphere 2003;52:1361–1371.CrossRefPubMedGoogle Scholar
  43. 43.
    Melchart D, Linde K, Weidenhammer W, Hager S, Shaw D, Bauer R. Liver enzyme elevations in patients treated with traditional Chinese medicine. JAMA 1999;282:28–29.CrossRefPubMedGoogle Scholar

Copyright information

© Chinese Association of the Integration of Traditional and Western Medicine and Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Xiao-chen Yang (杨晓忱)
    • 1
  • Xing-jiang Xiong (熊兴江)
    • 1
  • Guo-yan Yang (杨国彦)
    • 2
  • He-ran Wang (王贺冉)
    • 3
  • Jie Wang (王 阶)
    • 1
    Email author
  1. 1.Department of Cardiology, Guang’anmen HospitalChina Academy of Chinese Medical SciencesBeijingChina
  2. 2.Centre for Evidence-Based Chinese MedicineBeijing University of Chinese MedicineBeijingChina
  3. 3.Cancer Research InstituteCentral South UniversityChangshaChina

Personalised recommendations